Iparomlimab and tuvonralimab vs Volrustomig
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: PD-1 x CTLA-4 · full Non-Small Cell Lung Cancer pipeline
Iparomlimab and tuvonralimab
Marketed by Qilu Pharmaceutical
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2026 · NCT07271602 (registry estimate)
No aligned efficacy figure on record for this race.
Volrustomig
Developed by AstraZeneca
NCT05984277 · Phase 3 · active, not recruiting
eVOLVE-Lung02 was a randomized, open-label Phase 3 in 895 participants with metastatic non-small cell lung cancer with progression-free and overall survival as dual primary endpoints. An independent committee judged at an interim review that neither endpoint was likely to be met, and the sponsor stopped the trial. A randomized but open-label trial with a negative result is moderate evidence of no benefit.
Next expected readout: June 2027 · NCT04686305 (registry estimate)
Reported efficacy
Progression-Free Survival (PFS) (using BICR assessments according to RECIST 1.1) (Up to approximately 6 years); Overall Survival (OS), in PD-L1-negative participants. (Up to approximately 6 years): Dual primary endpoints (PFS and OS) not expected to be met: the IDMC concluded the volrustomig combination was unlikely to meet either, and AstraZeneca is discontinuing the trial (2026-08-17). (missed)
Result source: NCT05984277
Results for Non-Small Cell Lung Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Iparomlimab and tuvonralimab | Volrustomig |
|---|---|---|
| PFS, median | —Trial running · NCT05487391 | —Trial running · NCT05984277 |
| OS, median | —Trial running · NCT05487391 | —Trial running · NCT05984277 |
| ORR | —Trial running · NCT05487391 | —Trial running · NCT05984277 |
| Duration of response, median | —Trial running · NCT05487391 | —Trial running · NCT05984277 |
PFS, median
- Iparomlimab and tuvonralimab
- —Trial running · NCT05487391
- Volrustomig
- —Trial running · NCT05984277
OS, median
- Iparomlimab and tuvonralimab
- —Trial running · NCT05487391
- Volrustomig
- —Trial running · NCT05984277
ORR
- Iparomlimab and tuvonralimab
- —Trial running · NCT05487391
- Volrustomig
- —Trial running · NCT05984277
Duration of response, median
- Iparomlimab and tuvonralimab
- —Trial running · NCT05487391
- Volrustomig
- —Trial running · NCT05984277
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Iparomlimab and tuvonralimab: no structured comparison results are available for Non-Small Cell Lung Cancer.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Iparomlimab and tuvonralimab's landscape · Volrustomig's landscape